2024年2月29日 · GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases, obesity. Examples of drugs in this class include Exenatide, Liraglutide, Dulaglutide, and Semaglutide.

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable glucose-lowering medications approved for the treatment of adult patients with type 2 diabetes mellitus (T2DM). This article provides practical information to guide primary care physicians on the use of GLP-1RAs in patients …

2024年12月4日 · Glucagon-like peptide 1 (GLP-1)-based therapies (eg, GLP-1 receptor agonists, dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide [GIP] receptor agonists, dipeptidyl peptidase 4 [DPP-4] inhibitors) affect glucose control through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, [1] are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor.

2025年2月10日 · GLP-1 is a hormone that is released by L-cells in the intestine in response to food intake. Just like GLP-1, GLP-1 agonists attach to GLP-1 receptors, which subsequently has many effects that are helpful in treating type 2 diabetes and for weight loss. The mechanism of action (MOA) of GLP-1 agonists is multifactorial.

2018年4月3日 · Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion. GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting weight g …

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

This review will encompass the synthesis, secretion, and metabolism of GLP-1, the structure and expression of the GLP-1r, the intracellular signaling initiated by GLP-1r stimulation, and GLP-1 changes after bariatric surgery.

Dual glucose-dependent insulinotropic polypeptide (GIP)/ GLP-1 agonists bind to both the GIP and GLP-1 receptors but favor GIP receptor agonism over GLP-1. GIP inhibits gastric secretion activity, stimulates insulin secretion, and has insulin-like action on adipose tissue inhibiting lipolysis and promoting lipogenesis.

2018年12月1日 · A recombinant human glucagon-like peptide (GLP)-1–albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor–dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis